A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

ישראלמגייס משתתפיםPHASE3

מצבים רפואיים

Huntington Disease

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • University of CA San Diego, La Jolla, California, United States

    Contact: Study coordinator (Krisha Bagga) · kbagga@health.ucsd.edu · +1 858 249 0574
    Contact: Principal Investigator (Jody Corey-Bloom)
  • CenExcel Rocky Mtn Clin Research, Englewood, Colorado, United States

    Contact: Study coordinator (Liza Heap) · e.heap@cenexel.com · +1 303 762 6674
    Contact: Principal Investigator (Meagen Salinas)
  • Georgetown University, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Robin Kuprewicz) · rk1028@georgetown.edu
    Contact: Principal Investigator (Karen Anderson)
  • Parkinsons-Movement Disorder Ctr, Chicago, Illinois, United States

    Contact: Study coordinator (Zsa Zsa Brown) · zsazsa.brown@northwestern.edu · +1 312 503 5706
    Contact: Principal Investigator (Danny Bega)
  • University of Kansas Hospital, Fairway, Kansas, United States

    Contact: Study coordinator (Cameron Zoraghchi) · czoraghchi2@kumc.edu
    Contact: Principal Investigator (Richard Dubinsky)
  • Albany Medical College, Albany, New York, United States

    Contact: Study coordinator (Alicia Leader) · downeya@amc.edu · +1 518-262-5938
    Contact: Principal Investigator (Era Kaur Hanspal)
  • UBMD Neurology, Buffalo, New York, United States

    Contact: Study coordinator (Sonia Joseph) · joseph53@buffalo.edu · +1 716 932 6080
    Contact: Principal Investigator (Kelly Andrzejewski)
  • Columbia University Irving Medical, New York, New York, United States

    Contact: Study coordinator (Sandra Rizer) · sz2667@cumc.columbia.edu · +1 212 305 1718
    Contact: Principal Investigator (Karen Marder)
  • Cleveland Clinic Foundation, Cleveland, Ohio, United States

    Contact: Study coordinator (Margaret Andorf) · andorfm@ccf.org · +1 216 442 5232
    Contact: Principal Investigator (Adam Margolius)
  • University of Pennsylvania, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Gwenivere Toti) · gwenivere.toti@pennmedicine.upenn.edu
    Contact: Principal Investigator (Aaron Lasker)
  • Veracity Neuroscience LLC, Memphis, Tennessee, United States

    Contact: Study coordinator (Jennifer Marshall) · jennifer@veracityneuroscience.com · +1 901 237 3561
    Contact: Principal Investigator (Mark Steven LeDoux)
  • TX Movement Disorder Spec PLLC, Georgetown, Texas, United States

    Contact: Study coordinator (Wendy White) · wendy@txmds.net
    Contact: Principal Investigator (Michael Soileau)
  • U of TX Health Science Ct, Houston, Texas, United States

    Contact: Study coordinator (Dane Weinig) · Dane.R.Weinig@uth.tmc.edu · +1 832 325 7080
    Contact: Principal Investigator (Erin Furr Stimming)
  • University of Washington Medical Center, Seattle, Washington, United States

    Contact: Study coordinator (Debra Del Castillo) · debradel@uw.edu · +1 206 616 7117
    Contact: Principal Investigator (Suman Jayadev)
  • North York General Hospital, North York, Ontario, Canada

    Contact: Study coordinator (Clare Gibbons) · clare.gibbons@nygh.on.ca · +416 756 6788
    Contact: Principal Investigator (Ragini Srinivasan, MD)
  • Centre de recherche du CHUM, Montreal, Quebec, Canada

    Contact: Study coordinator (Martine Comeau) · martine.comeau.chum@ssss.gouv.qc.ca · +1514 890 8000
    Contact: Principal Investigator (Alby Richard)
  • CUSM Montreal Neurological Institute, Montreal, Quebec, Canada

    Contact: Study coordinator (Yara Nasr) · yara.nasr@mcgill.ca
    Contact: Principal Investigator (Anne-Louise Lafontaine)
  • Novartis Investigative Site, Chengdu, Sichuan, China

  • Tel Aviv Sourasky Med Ctr Ichilov, Tel Aviv, Israel

    Contact: Study coordinator (Tanya Gurevich) · tanyag@tlvmc.gov.il
    Contact: Principal Investigator (Tanya Gurevich)
  • Novartis Investigative Site, Seoul, Seoul, South Korea

  • Novartis Investigative Site, Taipei, Taiwan

  • Novartis Investigative Site, Exeter, Devon, United Kingdom

  • Novartis Investigative Site, Aberdeen, Grampian Region, United Kingdom

  • Novartis Investigative Site, Cardiff, United Kingdom

  • Novartis Investigative Site, Glasgow, United Kingdom

  • University College Hospital, London, United Kingdom

    Contact: Study coordinator (Kate Fayer) · k.fayer@ucl.ac.uk · 02031087483
    Contact: Principal Investigator (Sarah Tabrizi)
  • Southampton General Hospital, Southampton, United Kingdom

    Contact: Study coordinator (Giorgia Cortorillo) · giorgia.cortorillo@uhs.nhs.uk · 02381206132
    Contact: Principal Investigator (Christopher Kipps)